The first data in the FH Studies Collaboration registry show that among 42,000 adults with heterozygous FH, about half of patients received a statin and the majority was not at LDL-c goal.

The ELIPSE HoFH trial met its primary endpoint, showing that evinacumab lowered LDL-c by 49% from baseline in HoFH patients already on other lipid-lowering therapies, including PCSK9 inhibitors.

Lp(a) meeting The prevalence of clinical FH was investigated in the Copenhagen General Population Study with adjustment for the cholesterol content in Lp(a). Prof. Nordestgaard shares possible ways to interpret these results.

In >1 million blood donors, the prevalence of FH was similar to the estimated prevalence of FH in the general population. This suggests that donor screening may represent a new approach for FH screening and intervention.

EAS 2019 Prof. Kausik Ray talks about the Familial Hypercholesterolemia Studies Collaboration, which was established to address the unmet need to influence global policy change regarding screening for FH patients early in life.

A meta-analysis showed significantly elevated Lp(a) levels with statin therapy and a cell culture study demonstrated increased apo(a) production after statin treatment, which possibly contributes to the residual CV risk in subjects on statins.

9% Of adults who experience MI before 50 years of age, have probable or definite FH. Statin therapy is often suboptimal and so are LDL-c levels at 1 year post-MI.

EAS 2019 A UK study involving over 1.7 million health records in the general population suggests that a considerable number of people may have FH but are not diagnosed yet, leading to premature mortality

EAS 2019 An analysis of the 4S trial data suggests that people with characteristics suggestive of FH, gain greater clinical benefit from statin therapy, in reducing events and mortality.

LDL-c levels vary greatly among pediatric patients with genetically defined hoFH, and overlap exists between the LDL-c levels and phenotypes of severe heFH and hoFH.

The FDA has approved alirocumab to reduce the risk of MI, stroke, and unstable angina requiring hospitalization in adults with established CVD, based on ODYSSEY OUTCOMES data.

Safety of bempedoic acid was studied over a 1-year period in the CLEAR Harmony trial, which enrolled high CV risk patients.